Colorectal Carcinoma (CRC) ranks the third most commonly diagnosed cancer among both genders in the United States
of America. [1] CRC is a preventable disease, yet is a known major cause of cancer mortality and is considered to be greatly attributable to inappropriate lifestyle patterns. At a global level, CRC is responsible for an estimate of 8% of cancer-related deaths. [2] There are many reports from Asia and Africa, where the incidence of CRC in the young adults, was significantly higher compared to the Western literature [3, 4] and based on the cancer registry of The Gulf Cooperation Council (GCC) Countries of 1998-2007, the incidence of CRC was 40/100,000 in men and 32/100,000 in women. Compared to other GCC countries, Kingdom of Bahrain had higher incidence rates for CRC. It has also been found that more than 75% of discovered CRC cases were in advanced local, regional or systemic stages. [5, 6] Although Pakistan falls into the low-risk category of the worldwide for CRC, it seems that this may not be the case anymore with the increasing risk factors among the Pakistani population. [7] Factors known to increase the risk of cancer, such as smoking, physical inactivity, obesity and bad-diet regimen have been adapted by many worldwide, thus, increasing the burden of cancer, not just globally, but also in developing countries. [8, 9] The rise of the incidence of CRC in many Asian, as well as Eastern European countries, may reflect the increase in the prevalence of modifiable risk factors for this cancer, which include unhealthy diet, obesity and physical inactivity, and smoking. [10] According to a study conducted in New Zealand, the identifiable and major risk factors that played a role in CRC were excess alcohol consumption, tobacco smoking, diet containing both red and processed meats, obesity, and lack of physical activity. [11] Furthermore, the role of cigarette smoking was identified to cause microsatellite instability (MSI) which plays a role in the pathogenesis of CRC. Likewise, it was estimated that tobacco use was responsible for approximately 21% of colon cancers related to MSI. [12] In Korea, there is trend for CRC screening through fecal occult blood test (FOBT) and colonoscopy, which is the gold standard technique for the diagnosis of CRC. [12, 13] Colonoscopy is an invasiveness, expensive procedure compared to FOBT, yet, FOBT is being commonly used in the screening programs for the diagnosis of CRC all over the world due to its noninvasive, more acceptable nature. According to a previous meta-analysis studies, the sensitivity, specificity, and positive predictive value of immunochromatographic FOBT (IFOBT) in CRC were 67%, 85%, and 41%, respectively. [14] Recent emphases on the use of stool based molecular screening tests such as M2-Pyruvate Kinase (M2-PK) has been recently considered as a screening/triaging platform for CRC. The test is based on finding an isoenzyme of PK which is mainly produced in undifferentiated and proliferating body tissues. In neoplastic cells, M2-PK regulates the synthetic balance between ATP and macromolecules, which plays an important role in neoplastic growth and glycolysis during the process of carcinogenesis. The use of M2-PK test has been proved better than IFOBT in the detection of CRC and its precursors, i.e. the adenomatous polyps, but still being expensive or not available in most remote areas. [15, 16] The objectives of the study were, Firstly, to establish the prevalence of CRC precursors in the Kingdom of Bahrain, Secondly, to investigate the validity and reliability of stool based fecal tumor biomarker (M2-PK) test and Thirdly, to compare its sensitivity to that IFOB and perhaps to recommend this or similar stool based molecular test, as a potential replacement for the currently used IFOBT.
MatErials and MEthods

Approvals from Ministry of Health institutional
Research board (IRB) and King Hamad Hospital Directorate of Ethics and Research were obtained.
Design
Prospective, cross sectional study. 
Duration and place of study
Operational and participants flow
The study campaigning was organized in 4 Ministry of Health centers, each center represents one of the four Governorate of Bahrain (Central, Muharraq, Northern and Southern areas), alongside, three governmental hospitals and seven private sector hospitals/clinics. Individual's consultation and sample collection stations were controlled by the study project coordinators at King Hamad University Hospital (KHUH) in coordination with the other stations for patients consultation and sample collection stations in the four Government Hospitals of Bahrain [ Figure 1 ].
Figure 1: King Hamad University Hospital laboratory and other stations for patients consultation and sample collection stations in Governments Hospitals of Bahrain
During the campaign, all participating individuals were provided with several printable educational pamphlets and illustrational audiovisual materials, followed by head to head sessions for questions and answers discussion with health care professionals, ending by escorting participants in a walk-through a giant inflatable diseased colon for further education and raising awareness about serious CRD. Interested individuals been consented for a quick professional consultation and further education about the nature of the study, the need to submit a fully completed accompanied questioners and to submit at single stool sample for testing, and to expect a call for further medical consultation about their results and whether they need to go for screening colonoscopy and biopsy taken, if positive finding is found.
All stool samples were tested within 24 hours of submission and all results were crossed checked by two senior laboratory technologists and centralized at the microbiology section computer register at KHUH Laboratories along with photo image for each result. The results were then transferred and entered in another computer software program database for further statistical analysis. All Selected individuals based on the inclusion/exclusion criteria, were contacted via the study call center in groups within days of results retrieval of their stool samples.
Inclusion criteria
1. Asymptomatic fit individuals, males and females 2. Age: 45-74 years 3. Signed consent of enrolment in the study 4. Fully completed questionnaire and submission of a single stool sample.
Exclusion criteria
History of diagnosed or active cases of CRC.
EQUAL CHANCE to proceed with colonoscopy was achieved via phone calls from participating government and private sector hospitals which was overseen by the study control center at King Hamad University Hospital (KHUH), so participants can attend a fast track consultant clinic for further consultations and to proceed with performing colonoscopy procedures.
The tests
The study utilized two-stool based IFOB tests; one of which was the available kit within KHUH laboratories and being utilized for clinical use and the other one was Schebo ® 2 in 1 Quick™ (M2-PK + Hb) kit. The last was a commercially available, stool-based biomarker test, claimed with a superior reproducibility of 97% sensitivity and 98% specificity for detecting colorectal neoplasia at early stages.
Sampling technique
A single STOOL SAMPLE of Participating individual was collected at KHUH within 24 hours of sample submission, according to an agreed guidelines and logistics. The Same Stool Sample was subjected for two different kinds of tests; the regular detection of IFOB Rapid (Ministry Of Health approved) test and the Metabolic fecal tumor (M2-PK 2 in 1) biomarker test. Individuals with any Positive test would be advised to undertake subsequent colonoscopy and histopathology examination (if applicable) for confirmatory diagnosis. Tumor M2-PK test (ScheBo Biotech, Giessen, Germany), a sandwich ELISA based on two monoclonal antibodies specific for tumor M2-PK 2. The test allowed the quantitative measurement of tumor M2-PK in 4 mg of stool with a lower detection limit of 2 U ml.
All analyses were carried out in the KHUH laboratory under standardized conditions. THE COLONOSCOPY procedures were performed by participating hospitals' consultants for positive stool cases.
All colonoscopies were performed by either Consultant Gastroenterologist or a certified General Surgeons with special interest in Colonoscopy and according to the nomination by the participating hospitals.
Colonoscopy, in this study aimed mainly as a screening tool to detect presence of inert cancer or polyp, while it naturally has been used to confirm the presence of other lesions and to perform therapeutic procedures such as removing polyps etc.
Participating hospitals were agreed to be operational throughout the period of the study and be able to give an appointment for colonoscopy within 10 days of the first consultation and if this flow isn't achievable for any reason, then arrangement through the study call Centre for colonoscopy at another facility must be proceeded. Colonoscopy surveillance with or without biopsy removable of polyps or any cancerous/pre-cancerous lesions shall follow the accepted guidelines of the hospitals and out of preview of this study, i.e. Making sure that total colonoscopy with caecal intubation (visualization) is to be demonstrated in up 90% of all colonoscopy and if this cannot be achieved for anatomical reasons, virtual CT colonoscopy will be arranged.
If a suspicious lesion/polyp is found during colonoscopy, then a biopsy/polypectomy should take for histopathology verification by two independent consultant pathologists.
To assess the validity of the (M2-PK) test compared to the currently utilized IFOB, a positive and negative control groups were set up to insight the sensitivity of the new M2-PK tumor biomarker test.
Negative control group
Fifty participating individuals with negative stool (M2-PK/IFOB) tests were consented for a checkup colonoscopy and considered as Negative Control Group based on their no objection for the procedure.
Positive control group
Fifty symptomatic patients outside the study individuals, who underwent colonoscopy for various complaints and found to have CDC proved by a histopathology biopsy confirmation were asked through their concerned surgeons to collect a single stool sample each for (M2-PK/IFOB) test before their definitive surgery. Their stool samples were tested and showed positive M2-PK results, while the IFOB test showed mixed findings.
rEsults
There were a total of 2100 participants, who filled the questioners, but only 1700 participants were selected, according to the selection criteria. Most of the participants, among those selected persons, did not respond and only 1074 participants submitted their stool samples. The age range of the participants was wide (25-74,) but the mean age of the patients was 52.78 ± 11.52. Only 105 of participants whom their stool tests were positive for M2-PK agreed later with difficulty to undertaken colonoscopies [ Table 1 ]. There were 64 males and 41 (with ration of 1:1.5). There were 494 (46%) persons positive for M2-PK test, while 179 (16.6%) were positive by IFOB.
The Results for both positive and negative M2-pyruvate kinase test in 105 individuals are shown in [ Figure 2 ].
Among these positive cases, and the only 105 participants who agreed to underwent full colonoscopies, 20 showed positive lesions while 85 were found negative for neoplastic disease. Of these, 85 (81%) patients were suffering from miscellaneous lesions and only 20 (19%) cases showed neoplastic lesion. Of these neoplastic 20 findings, 17 (85%) were of adenomatous polyps, 02 (10%) adenocarcinomas, and 01 (5%) neuroendocrine carcinoma (NEC). The adenomatous polyps included 09 tubular adenomas, 01 villous adenoma, and 07 tubulovillous adenomas [ Figures 3 and 4 ]. The morphology of 85 negative cases included a mixture of other and non-neoplastic histology. These were polyps but normal mucosa 6 cases, hemorrhoids 13 cases, hyperplastic polyps 6 cases, normal mucosa but no biopsy 31 cases, normal mucosa 10 cases, diverticulosis 9 cases, angiodysplasia 1 case, inflammatory bowel disease 1 case, and solitary rectal ulcer 1 case [ Figure 5 ]. Among these 4 cases of IFOB positive but M2-PK negative whom underwent colonoscopy, no neoplastic lesion was found. Two cases were due to hemorrhoids, and other two were normal [ Figure 6 ]. Twelve cases were missed by IFOB but were picked by M2-PK, 11 were adenomatous polyps and 1 was NET [ Figure 7 ]. discussion CRC is a leading cause of death worldwide, including the Kingdom of Bahrain and large numbers of newly diagnosed malignant neoplasms belong to this category as in United States of America. CDC is the third most common cancer affecting both males and females. [1, 16] As a matter of fact, CRC is a preventable and potentially curable healthcare problem in the Kingdom of Bahrain, yet, no well-established national screening program for early detection and management of Tests. The evolving principle of detecting Fecal Tumor Biomarker(s) stands in response to the limitation of the currently used fecal occult blood tests and being more specific, utilizing one stool sample instead of three consecutive samples while participating individual needs not to be on certain dietary or medication control. The faecal pyruvate kinase isoenzyme type M2 (faecal M2-PK) test recognizes a key enzyme controlling the metabolism of cells with a high proliferation rate, such as tumor cells, and thereby detects specific alterations in intestinal cells, such as polyps and cancers. This dimeric form of PK enzyme and its level increase with the developing stages of CRC from polyps. It has been claimed the same idea apply to high-risk patients with chronic Inflammatory bowel diseases (not our study subject). M2-PK is a special isoenzyme of pyruvate kinase, a key enzyme within glycolysis which catalyzes the ATP-producing conversion of phosphoenolpyruvate (PEP) to pyruvate.
Depending upon the metabolic functions of the tissues, different isoenzymes of pyruvate kinase are expressed and during tumor formation, the tissue-specific isoenzymes disappear and the pyruvate kinase isoenzyme type M2 is expressed. [17] The early detection by different screening methods has improved the prognosis of CRC. No doubt, the efficacy of stool-based screening methods is low compared to gold standard method, i.e. colonoscopy, but they are feasible and cost-effective techniques and the utilization of a more specific and sensitive stool based molecular techniques such M2-PK alone or in combination with the IFOB tests enhance the detection rate, providing those individuals are followed by a prompt colonoscopy examination in order to increase the screening performance for CRC at early stage. [18] The age range of the participants in our study was quite wide (25-74,) but the mean age of the individuals was 52.78 ± 11.52; there were 64 males and 41 females (with ration of 1:1.5). It is not consistent with the study of Kim et al., who found the mean age at the time of CRC diagnosis was 39.3 years (range 18-59 years). [19] In our study, there were 494 (46%) persons positive for M2-PK test, while 179 (16.6%) were positive by IFOB. Only 105 of participants who were positive either by M2-PK or IFOB or both undertook colonoscopies, It was not surprising that, out of 494 cases positive cases, only 105 of participants agreed for further colonoscopies as a line of screening for CDC, and this reflects several personal, social and educational factors, which are highlighted in the preceding text. The sensitivity of the M2-PK was found high as compared to IFOB, and our study is consistent with the other studies mentioned in literature. [18, 20] Among those 105 colonoscopy findings, 20 revealed positive lesions while 85 were found negative for neoplastic disease. The frequency of the neoplastic lesions was low as compared to other non-neoplastic lesions, whowever, these 20 neoplastic cases are quite significant. The total of 17 (85%) adenomatous polyps, 02 (10%) adenocarcinoma, and 01 (5%) Neuroendocrine tumour are detected and treated at an earlier 
Individuals prospect challenges
Colonoscopy as a screening modality of asymptomatic population is not quite acceptable in Bahrain cultures. Fear of disturbing normal lifestyle and the stigma of having diagnosed with cancer is a major personal concern, especially, the impact and drawback on their self-sponsored medical insurance cover and fear of losing job.
Government prospect
The Cost of treatment of CRC patients approximate BD 2.500 -BD 10.000, if not more in advanced cases. The recent statistics from Bahrain Cancer register reflects an increasing trend for CRC, therefore, it is the time to take a serous measures toward establishing a National Screening Programer for Colorectal Cancers in the Kingdom of Bahrain with all required backup support toward mass education, to ease the culture acceptance and overcome social Barriers. Providing the right employed organizational structure and fund for its success is of paramount importance, especially deployment of the most sensitive stool based platform test, i.e.: utilizing a molecular based test wither alone or in combination with the currently used IFOBT as being followed by most international established NSPCC in Europe and north America.
Recommendations
Our Preliminary results recommend the following: Substituting the currently used primary IFOB screening test for a population-based colorectal screening program with a new stool based tumor Biomarker test to primarily prevent the disease (Behavior Change), Secondly, to early detect the disease (by a well-structured colorectal cancer screening programs) and thirdly, to stop further disease spread (metabolic control) as tertiary prevention.
The screening may affect on prevention of CRC and to reduce mortality, stop morbidity and enhance the quality of life, through early detection and treating the precancerous polyps and early detection of CRC.
Comprehend the targeted population for evidence-based screening program and suggest further studies to start screening men and women at age of 45 with a screening interval as per the current international guidelines.
Finally, the colonoscopy must be offered to those individuals who test positive for the new biomarker tests.
conclusion
Colonoscopy is the gold standard for diagnosis of CRC but is an invasive and time-consuming technique. The screening of CRD by a stool based molecular test such as M2-PK have shown a high sensitivity for the detection of CRC and adenomatous polyps compared to IFOBT. Fecal M2-PK is a cost-effective, easy to perform, as an adjunct a non-invasive pre-colonoscopy CRC screening test for individuals once reached age of 45 years. stage. The 9 tubular adenomas, 01 villous adenoma, and 07 tubulovillous adenomas were all removed and all patients are now registered for healthcare follow up. The detection of CRD was almost 100% with the used of this combined IFOB/M2-PK kit, and the results of the variation of deferent IFOB kits will be evaluated in a different study, but what matter is that all 105 cases were found having one or other type of RCD and despite 20 cases of normal mucosa with normal biopsy, 9 diverticulosis, 1 angiodysplasia, 1 IBD, and 1 solitary rectal ulcer all were detected in subclinical stage.
The 4 cases of iFOB positive but M2-PK negative individuals who had colonoscopy performed, no neoplastic lesion was found. Two cases were of hemorrhoid, and other two were normal, therefore, when compared the specificity of both screening stool tests, the M2-PK was much better as compared to IFOB because 12 cases were missed by IFOB but were picked by M2-PK, all findings here were significant and included 11 adenomatous polyps and 1 Neuroendocrine carcinoma.
In our study, the sensitivity of M2-PK for CRC was 96%, which was superior to IFOBT (32%, P < 0.001) [ Figure 8 ]. These findings are almost consistent with Koss et al. [21, 22] The issue of false positivity of M2-PK must be addressed and studied further in a wider range that might also consider performing upper GIT endoscopy.
Challenges and recommendations General challenges
We experienced several difficulties to obtain major research fund, passed through variable coordination issues at all levels with many communication halts, delay and resistance. Also, finding a competent specialized data Computer system software was a major drawback with missing curtails individual information related to history and complete healthcare register, mainly due to incomplete data entry and difficult data retrieval.
Media Exposure and frequent proper cancer education programs and lack of a well-established patient education centers within major hospital is not consistent or not existing at all and mainly due to lack of specialized manpower. 
